Mendy Maccabee, MD
Otolaryngology · Hood River, ORNPI 1205927134
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,122 of the $1,467 with a category attached, or 76.5%. It is spread thinly across 14 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $322, 2.9 times the $113 reported in 2019.
Across 48 payments — averaging $30.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$296
- GSK$195
- Regeneron Healthcare Solutions, Inc.$179
- Sanofi$163
- Medtronic$150
- Intersect ENT, Inc.$103
- plus $382 from 8 others
What the payments were for
- Consulting fees$15010%
- Food & beverage$1,12276%
- Education$19513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $296 |
| GSK | 8 | $195 |
| Regeneron Healthcare Solutions, Inc. | 6 | $179 |
| Sanofi | 8 | $163 |
| Medtronic | 1 | $150 |
| Intersect ENT, Inc. | 3 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Merz North America, Inc. | 1 | $78 |
| Stryker | 1 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Novartis | 2 | $39 |
| Baxter Healthcare | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $16 |
How this compares
$1,467 in reported general payments places this provider in the 65th percentile of 128 otolaryngology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FasenraBenralizumab | 16 | $94,672 |
| Dupixent SyringeDupilumab | 15 | $62,451 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $27,613 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $23,243 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,317 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $4,269 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,778 |
| Epinephrine | 16 | $3,324 |
| Ofloxacin | 20 | $1,218 |
| SynthroidLevothyroxine Sodium | 17 | $1,133 |
| Ipratropium Bromide | 47 | $1,084 |
| Fluticasone Propionate | 65 | $1,001 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $736 |
| Famotidine | 38 | $490 |
| Mupirocin | 54 | $450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Symbicort | $296 | $103,98942 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $195 | $50,85681 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 128 otolaryngology providers in Oregon.
Other otolaryngology in Hood River
- Mathew GeltzeilerPortland$221K
- Ryan LiPortland$160K
- Jeremiah AltPortland$89K
- Mark WaxPortland$20K
- Marcus MonroePortland$16K
- Joshua SchindlerPortland$8K
- Andrew BakerMilwaukie$8K
- Daniel ClayburghPortland$7K
- Timothy HullarPortland$7K
- Paul FlintPortland$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.